Roux, Damien http://orcid.org/0000-0002-6103-6416
Benichou, Nicolas
Hajage, David
Martin-Lefèvre, Laurent
de Prost, Nicolas
Lerolle, Nicolas
Titeca-Beauport, Dimitri
Boulet, Eric
Mayaux, Julien
Mégarbane, Bruno
Mahjoub, Khaoula
Carpentier, Dorothée
Nseir, Saad
Tubach, Florence
Ricard, Jean-Damien
Dreyfuss, Didier
Gaudry, Stéphane
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study—an ancillary study of a randomized controlled trial
https://doi.org/10.1186/s13613-023-01105-0
Funding for this research was provided by:
Programme Hospitalier de Recherche Clinique National (AOM12456)
Article History
Received: 15 November 2022
Accepted: 2 February 2023
First Online: 25 February 2023
Declarations
:
: The protocol (which has been published previously 23) was approved by the ethics committee of the French Society of Intensive Care Medicine and by the appropriate French legal authority (Comité de Protection des Personnes d’Ile de France VI) for all participating centers. The investigators informed patients or their surrogates about the trial both orally and with a written document. In accordance with French law, written informed consent was not required, because the standard of care encompasses both study interventions. Patients or their surrogates were informed that they could decline to participate at any time, and their decision was recorded in patient files. The AKIKI trial was registered on ClinicalTrials.gov (Identifier: NCT01932190) before the inclusion of the first patient.
: Not applicable.
: The authors declare that they have no competing interests.